Bulletin 2011/51 - European Patent Office
26.02.2013 • Views
Share Embed Flag

Bulletin 2011/51 - European Patent Office

Bulletin 2011/51 - European Patent Office

Bulletin 2011/51 - European Patent Office

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
application.epo.org

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

(A61K) I.1(1)<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

(86) US 2010/024127 12.02.2010<br />

(87) WO 2010/093944 2010/33 19.08.2010<br />

(88) 11.08.<strong>2011</strong><br />

(30) 13.02.2009 US 152608 P<br />

(54) • AMORPHES CDDO-ME ENTHALTENDE<br />

ORALE DOSIERZUSAMMENSETZUNGEN<br />

MIT VERZÖGERTER FREISETZUNG<br />

• DELAYED RELEASE, ORAL DOSAGE<br />

COMPOSITIONS THAT CONTAIN AMOR-<br />

PHOUS CDDO-ME<br />

• LIBÉRATION CONTRÔLÉE, COMPOSI-<br />

TIONS ORALES DE DOSAGE CONTENANT<br />

DU CDDO-ME AMORPHE<br />

(71) Reata Pharmaceuticals, Inc., 2801 Gateway<br />

Drive, Suite 150, Irving, TX 75063-2648, US<br />

(72) ZHANG, Jiang, Coppell Texas 75019, US<br />

MEYER, Colin J., Frisco Texas 75034, US<br />

(74) Plougmann & Vingtoft A/S, Sundkrogsgade<br />

9 P.O. Box 831, 2100 Copenhagen Ø, DK<br />

A61K 9/16 → (<strong>51</strong>) A61K 9/00<br />

A61K 9/16 → (<strong>51</strong>) A61K 9/14<br />

A61K 9/16 → (<strong>51</strong>) C08G 69/48<br />

A61K 9/20 → (<strong>51</strong>) A61K 9/00<br />

A61K 9/20 → (<strong>51</strong>) A61K 31/155<br />

A61K 9/20 → (<strong>51</strong>) A61K 31/443<br />

(<strong>51</strong>) A61K 9/22 (11) 2 395 980 A1*<br />

A61K 31/445 A61P 29/00<br />

A61K 47/34 A61K 31/485<br />

A61K 31/415<br />

(25) En (26) En<br />

(21) 098401<strong>51</strong>.6 (22) 17.04.2009<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK TR<br />

(86) US 2009/040956 17.04.2009<br />

(87) WO 2010/093374 2010/33 19.08.2010<br />

(30) 10.02.2009 US 1<strong>51</strong>390 P<br />

14.04.2009 US 423201<br />

(54) • ZUSAMMENSETZUNGEN UND VERFAH-<br />

REN ZUR BEHANDLUNG VON POSTOPE-<br />

RATIVEN SCHMERZEN MIT BUPIVACAIN<br />

UND EINEM ENTZÜNDUNGSHEMMENDEN<br />

MITTEL<br />

• COMPOSITIONS AND METHODS FOR<br />

TREATING POST-OPERATIVE PAIN USING<br />

BUPIVACAINE AND AN ANTI-INFLAMMA-<br />

TORY AGENT<br />

• COMPOSITIONS ET METHODES DE TRAI-<br />

TEMENT DE LA DOULEUR POST-OPERA-<br />

TOIRE AU MOYEN DE BUPIVACAÏNE ET<br />

D'UN AGENT ANTI-INFLAMMATOIRE<br />

(71) Warsaw Orthopedic, Inc., 2500 Silveus<br />

Crossing, Warsaw, IN 46581, US<br />

(72) WOHABREBBI, Amira, Memphis TN 38103,<br />

US<br />

(74) Hally, Anna-Louise, FRKelly 27 Clyde Road,<br />

Dublin 4, IE<br />

(<strong>51</strong>) A61K 9/22 (11) 2 395 981 A2*<br />

A61K 47/34 A61K 47/06<br />

A61K 41/00<br />

(25) En (26) En<br />

(21) 10741563.0 (22) 01.02.2010<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

(86) US 2010/022769 01.02.2010<br />

(87) WO 2010/093528 2010/33 19.08.2010<br />

(88) 31.03.<strong>2011</strong><br />

Europäisches <strong>Patent</strong>blatt<br />

<strong>European</strong> <strong>Patent</strong> <strong>Bulletin</strong><br />

<strong>Bulletin</strong> européen des brevets<br />

(30) 10.02.2009 US 1<strong>51</strong>277 P<br />

(54) • REVERSIBLE WIRKSTOFFFREISETZUNG<br />

NACH BEDARF ÜBER EXTERNEN HINWEIS<br />

• ON-DEMAND AND REVERSIBLE DRUG<br />

RELEASE BY EXTERNAL CUE<br />

• LIBÉRATION DE MÉDICAMENT À LA<br />

DEMANDE ET RÉVERSIBLE PAR REPÈRE<br />

EXTÉRIEUR<br />

(71) President and Fellows of Harvard College, 17<br />

Quincy Street, Cambridge, MA 02138, US<br />

(72) ZHAO, Xuanhe, Cambridge, Massachusetts<br />

02138, US<br />

HUEBSCH, Nathaniel, D., Sommerville, Massachusetts<br />

02143, US<br />

MOONEY, David, J., Sudbury, Massachusetts<br />

01776, US<br />

SUO, Zhigang, Lexington, Massachusetts<br />

02420, US<br />

(74) Crease, Devanand John, et al, Keltie LLP<br />

Fleet Place House 2 Fleet Place, London<br />

EC4M 7ET, GB<br />

A61K 9/22 → (<strong>51</strong>) A61K 47/04<br />

A61K 9/28 → (<strong>51</strong>) A61K 31/155<br />

A61K 9/48 → (<strong>51</strong>) A61K 31/155<br />

(<strong>51</strong>) A61K 9/70 (11) 2 395 982 A2*<br />

A61K 31/7036<br />

(25) En (26) En<br />

(21) 09805977.7 (22) 21.12.2009<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

(86) US 2009/069024 21.12.2009<br />

(87) WO 2010/075298 2010/26 01.07.2010<br />

(88) 13.01.<strong>2011</strong><br />

(30) 23.12.2008 US 140492 P<br />

23.12.2008 US 140486 P<br />

23.12.2008 US 140449 P<br />

23.12.2008 US 140468 P<br />

23.12.2008 US 140476 P<br />

23.12.2008 US 140417 P<br />

(54) • IMPLANTIERBARES KOMPOSITMATERIAL<br />

MIT EINEM KLEBRIGEN BIOKOMPATIB-<br />

LEN POLYMERFILM UND EINEM FREI-<br />

SETZBAREN BIOLOGISCH WIRKSAMEN<br />

MITTEL<br />

• AN IMPLANTABLE COMPOSITE COM-<br />

PRISING A TACKY BIOCOMPATIBLE<br />

POLYMER FILM AND A RELEASABLE<br />

BIOACTIVE AGENT<br />

• COMPOSITES IMPLANTABLES ET COM-<br />

POSITIONS COMPRENANT DES AGENTS<br />

BIOLOGIQUEMENT ACTIFS LIBÉRABLES<br />

(71) Surmodics Pharmaceuticals, Inc., 756 Tom<br />

Martin Drive, Birmingham, AL 35211, US<br />

(72) TIPTON, Arthur, J., Homewood AL 35209,<br />

US<br />

BURTON, Kevin, W., Hoover AL 35226, US<br />

TICE, Thomas, R., Indian Springs AL 3<strong>51</strong>24,<br />

US<br />

BOWMAN, Howard, Birmingham AL 35242,<br />

US<br />

BIGGS, Danielle, Memphis TN 38132, US<br />

MARKLAND, Peter, Birmingham AL 35244,<br />

US<br />

(74) Leissler-Gerstl, Gabriele, Hoefer & Partner<br />

<strong>Patent</strong>anwälte Pilgersheimer Straße 20, D-<br />

81543 München, DE<br />

A61K 9/70 → (<strong>51</strong>) A41B 17/00<br />

A61K 9/70 → (<strong>51</strong>) A61K 9/00<br />

(<strong>51</strong>) A61K 31/00 (11) 2 395 983 A1*<br />

A61K 31/155 A61K 31/198<br />

A61K 31/341 A61K 31/3<strong>51</strong><br />

36<br />

Anmeldungen<br />

Applications<br />

Demandes (<strong>51</strong>/<strong>2011</strong>) 21.12.<strong>2011</strong><br />

A61K 31/39 A61K 31/403<br />

A61K 31/4439 A61K 31/70<br />

A61K 31/7004 A61K 31/7008<br />

A61K 31/06 A61P 3/06<br />

A61P 3/08 A61P 3/10<br />

(25) En (26) En<br />

(21) 10703288.0 (22) 11.02.2010<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

BA RS<br />

(86) EP 2010/0<strong>51</strong>736 11.02.2010<br />

(87) WO 2010/092125 2010/33 19.08.2010<br />

(30) 13.02.2009 US 152302 P<br />

(54) • PHARMAZEUTISCHE ZUSAMMENSET-<br />

ZUNG MIT EINEM SGLT2-INHIBITOR,<br />

EINEM DPP-IV-INHIBITOR UND OPTIONAL<br />

EINEM WEITEREN ANTIDIABETISCHEN<br />

MITTEL UND IHRE VERWENDUNG<br />

• PHARMACEUTICAL COMPOSITION COM-<br />

PRISING A SGLT2 INHIBITOR, A DPP-IV<br />

INHIBITOR AND OPTIONALLY A FURTHER<br />

ANTIDIABETIC AGENT AND USES<br />

THEREOF<br />

• COMPOSITION PHARMACEUTIQUE<br />

CONTENANT UN INHIBITEUR SGLT-2, UN<br />

INHIBITEUR DPP-IV ET FACULTATIVE-<br />

MENT UN AUTRE AGENT ANTIDIABÉ-<br />

TIQUE ET SES UTILISATIONS<br />

(71) Boehringer Ingelheim International GmbH,<br />

Binger Strasse 173, 55216 Ingelheim am<br />

Rhein, DE<br />

(72) EICKELMANN, Peter, 55216 Ingelheim Am<br />

Rhein, DE<br />

MARK,Michael, 55216 Ingelheim Am Rhein,<br />

DE<br />

SEMAN, Leo John, Ridgefield, CT 06877, US<br />

THOMAS, Leo, 55216 Ingelheim Am Rhein,<br />

DE<br />

BROEDL, Uli, 55216 Ingelheim Am Rhein, DE<br />

GREMPLER, Rolf, 55216 Ingelheim Am<br />

Rhein, DE<br />

(74) Hammann, Heinz, Boehringer Ingelheim<br />

GmbH Corporate <strong>Patent</strong>s Binger Strasse 173,<br />

55216 Ingelheim am Rhein, DE<br />

(<strong>51</strong>) A61K 31/00 (11) 2 395 984 A1*<br />

A61K 31/70 A61K 31/7004<br />

A61K 31/7008 A61K 45/06<br />

A61P 3/06 A61P 3/08<br />

A61P 3/10 A61K 31/522<br />

(25) En (26) En<br />

(21) 10703474.6 (22) 11.02.2010<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

BA RS<br />

(86) EP 2010/0<strong>51</strong>735 11.02.2010<br />

(87) WO 2010/092124 2010/33 19.08.2010<br />

(30) 13.02.2009 US 152306 P<br />

(54) • PHARMAZEUTISCHE ZUSAMMENSET-<br />

ZUNG MIT LINAGLIPTIN UND OPTIONAL<br />

EINEM SGLT2-INHIBITOR UND IHRE<br />

VERWENDUNG<br />

• PHARMACEUTICAL COMPOSITION COM-<br />

PRISING LINAGLIPTIN AND OPTIONALLY<br />

A SGLT2 INHIBITOR, AND USES THEREOF<br />

• COMPOSITION PHARMACEUTIQUE<br />

CONTENANT DE LA LINAGLIPTINE ET<br />

FACULTATIVEMENT UN INHIBITEUR<br />

SGLT-2, ET SES UTILISATIONS<br />

(71) Boehringer Ingelheim International GmbH,<br />

Binger Strasse 173, 55216 Ingelheim, DE<br />

(72) EISENREICH, Wolfram, 55216 Ingelheim Am<br />

Rhein, DE

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!